about
Local nasal immunotherapy for allergic rhinitisLocal nasal immunotherapy for allergic rhinitisAllergen injection immunotherapy for seasonal allergic rhinitisHuman IgG4: a structural perspectiveNanoparticulate adjuvants and delivery systems for allergen immunotherapyNovel developments in the mechanisms of immune tolerance to allergensThe role of protein glycosylation in allergyBiological toxicity and inflammatory response of semi-single-walled carbon nanotubesAnalysis of complex patterns of human exposure and immunity to Schistosomiasis mansoni: the influence of age, sex, ethnicity and IgEMechanisms of Heightened Airway Sensitivity and Responses to Inhaled SO2 in AsthmaticsAllergen-specific immunotherapy: is it vaccination against toxins after all?Molecular characterization of major cat allergen Fel d 1: expression of heterodimer by use of a baculovirus expression system.Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in ChildrenIgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB.Insulin-like growth factor-2 enhances functions of antigen (Ag)-specific regulatory B cells.Mechanisms Mediating Pediatric Severe Asthma and Potential Novel Therapies.Generation of a chimeric dust mite hypoallergen using DNA shuffling for application in allergen-specific immunotherapy.Allergy-associated T cell epitope repertoires are surprisingly diverse and include non-IgE reactive antigens.A novel and well tolerated mite allergoid subcutaneous immunotherapy: evidence of clinical and immunologic efficacyImmune mechanisms of allergen-specific sublingual immunotherapy.Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitizationFel d 1-airway inflammation prevention and treatment by co-immunization vaccine via induction of CD4+CD25-Foxp3+ Treg cellsRapid polyclonal desensitization with antibodies to IgE and FcεRIαIntralymphatic immunotherapyIdentification of novel peptide biomarkers to predict safety and efficacy of cow's milk oral immunotherapy by peptide microarray.The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses.Tolerizing allergic responses in the lung.Regulatory T cells in asthma.CD4CD25 regulatory T lymphocytes in allergy and asthma.Human regulatory T cells: a unique, stable thymic subset or a reversible peripheral state of differentiation?Signaling through Fc gamma RIII is required for optimal T helper type (Th)2 responses and Th2-mediated airway inflammation.T regulatory cells and the control of allergic disease.The regulation of allergy and asthma.Sublingual immunotherapy of allergic diseases.Local mucosal immunoglobulin E production: does allergy exist in non-allergic rhinitis?The impact of pollen-related food allergens on pollen allergy.Immunomodulation: the future cure for allergic diseases.Synergistic effect of various regulatory factors in TH1/TH2 balance; immunotherapeutic approaches in asthma.Cross-reactivity in Grasses: Biochemical Attributes Define Exemplar Relevance.Thymic Stromal Lymphopoietin Enhances Th2/Th22 and Reduces IL-17A in Protease-Allergen-Induced Airways Inflammation.
P2860
Q24187849-E4E200BE-3971-4B92-AF12-F076D7C17EA8Q24242771-2E30E1FA-58C6-4BDE-AB54-7495CD783C1CQ24243115-28D65D57-A98E-42C8-A8C3-BB227D287D79Q26779758-AC317ABE-765E-47D5-B399-86A0F9F0AAC2Q26825418-5D28A053-E342-4850-88F0-8A2E2C1D8556Q27025655-1BDD50F8-8354-4FF8-92BF-D470F3651445Q28267829-55EAFD07-EAE9-46D9-ABE3-8C04B63EDD5BQ28392447-CF9F6E87-7A40-40EF-B807-D5E711A848D0Q28475501-329730DF-E797-4F5F-BB80-6BEBD552357BQ28650408-21017FC8-DE6E-4CDD-955D-391939D22A9CQ30248317-57ABE29D-B17C-4EE8-BB1B-600B7E6A9CF5Q31128689-7986E9B1-A2B0-42EF-BDE2-BEF2B41A587AQ33586188-B9600415-BFDC-4001-98FC-4BF8C6050B92Q33770788-E5C2222E-A0CC-44D6-9900-C3CDD1920A50Q33793070-E56B1CC3-352A-4843-A5FA-2A7BE1003A29Q33871749-4BE8AA8A-AD01-41E2-BB11-900ABE2E5F77Q34028890-73AB610B-AB6A-4465-8909-1F3287916655Q34410291-F3E4018C-1730-4629-8894-1DF91C53E4FFQ34442836-422FFEE4-C794-49C7-A5AA-EED8C858613AQ34484071-038553A4-8EE6-4C25-AD8A-700C745BDA43Q34640733-3120B348-50F9-447A-8959-DE36886CE7CDQ34647312-F247E4B2-E420-47FE-9F2A-E81301265462Q35125056-88623CAE-8ADE-4948-8B49-3A93C6602C04Q35155423-836048CF-512E-40CC-8A38-AF8F5DFD79E7Q35577578-78F2D1A9-EEA7-44C7-B5F2-35B1D73C0922Q35915934-730AD59B-D6DD-4CB8-9821-424D578DF2A0Q36054136-3126FB3A-46D9-45DD-B167-831E62E02DABQ36064548-CD75E428-0246-46EE-BDEE-4ED688C9060EQ36169760-7B66CF02-99CD-422A-9E7A-21AC75FBFB4BQ36171406-DBE281BA-9C9E-48D5-AA02-8A8C4258CB3DQ36229572-3983C1BD-47FD-4F1D-A060-74EAF0C82833Q36377204-335AD528-611F-4A38-AE72-D2A938CEF458Q36563540-A52C90A2-848C-4578-83B7-51076388A774Q36583727-3B9301FB-9D1E-4B31-89AA-2E210DC69C22Q36643795-8B053685-A660-4D74-A4E1-04CAC2F26EBAQ36677683-8B139E33-28F5-43EB-AEC6-D03B1409F87AQ36693947-30722984-9005-493A-82DB-4812D49337CDQ36735354-E06EB35F-F1E8-4418-99CA-299AF6F83D94Q36834795-10206FF8-AE68-45F9-9CF9-7DB18ED35A74Q36857057-3E6FC5DE-F205-481E-9CE7-300DBEE88F71
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Mechanisms of immunotherapy.
@ast
Mechanisms of immunotherapy.
@en
type
label
Mechanisms of immunotherapy.
@ast
Mechanisms of immunotherapy.
@en
prefLabel
Mechanisms of immunotherapy.
@ast
Mechanisms of immunotherapy.
@en
P2093
P1476
Mechanisms of immunotherapy
@en
P2093
James N Francis
Kayhan Nouri-Aria
Stephen R Durham
P304
1025-34; quiz 1035
P356
10.1016/J.JACI.2004.03.024
P407
P577
2004-06-01T00:00:00Z